Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but no
Author: ["Scott L. Gottlieb","Patricia Gilleaudeau","Ray Johnson","Len Estes","Thasia G. Woodworth","Alice B. Gottlieb","James G. Krueger"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Psoriasis is a hyperproliferative and inflammatory skin disorder of unknown aetiology. A fusion protein composed of human interleukin-2 and fragments of diphtheria toxin (DAB389IL-2), which selectively blocks the growth of activated lymphocytes but not keratinocytes, was administered systemically to ten patients to gauge the contribution of activated T cells to the disease. Four patients showed striking clinical improvement and four moderate improvement, after two cycles of low dose IL-2–toxin. The reversal of several molecular markers of epidermal dysfunction was associated with a marked reduction in intraepidermal CD3+ and CD8+ T cells, suggesting a primary immunological basis for this widespread disorder.
Cite this article
Gottlieb, S., Gilleaudeau, P., Johnson, R. et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1, 442–447 (1995). https://doi.org/10.1038/nm0595-442
